Octapharma Nears Completion on $1.5 Billion South Carolina Manufacturing Facility
Octapharma, a Swiss biopharmaceutical company, is finalizing a $1.5 billion manufacturing project in Rock Hill, South Carolina, which is expected to create 1,500 jobs.
Charlotte, NC, July 29, 2026 —
ROCK HILL, SC – Octapharma, a global biopharmaceutical company headquartered in Switzerland, is nearing the final stages of its substantial manufacturing project in Rock Hill, South Carolina. The initiative represents a significant investment of $1.5 billion and is projected to generate approximately 1,500 new jobs in the region.
The development, located in Rock Hill, marks a major expansion for Octapharma, which specializes in the production of therapeutic proteins derived from human plasma. This new facility is anticipated to bolster the company’s manufacturing capacity and contribute to its global supply chain for critical medicines.
Details regarding the specific timeline for the project’s completion were not provided in the summary. However, the company’s commitment to the Rock Hill site underscores its strategic focus on expanding its operational footprint in the United States. The creation of 1,500 jobs is expected to have a considerable economic impact on Rock Hill and the surrounding areas, offering a range of employment opportunities across various skill levels.
Further information on the operational status and full employment numbers will likely be released as the manufacturing project reaches its conclusion.
Story summarized from the original created by WFAE staff and wire reports on www.wfae.org, see more information here.
